Tocilizumab plus chemoimmunotherapy for advanced colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of medications for people with locally advanced colon cancer. It aims to see if adding tocilizumab to standard chemo-immunotherapy can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colon cancer that has not been treated yet.
- Your tumor is at least 10 cm away from your anus.
- You are between 18 and 80 years old.
- You are in generally good health (able to do normal daily activities).
- You do not have active infections or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combination for people with locally advanced colon cancer that has not spread. It combines a cholesterol-lowering drug (tafolecimab) with standard chemotherapy and immunotherapy before surgery, to see if it helps shrink the tumor and improve outcomes.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.